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Congenital infection by human cytomegalovirus (HCMV) is a leading cause of congenital
abnormalities of the central nervous system. Placenta infection by HCMV allows for viral
spread to fetus and may result in intrauterine growth restriction, preeclampsia-like symp-
toms, or miscarriages. We previously reported that HCMV activates peroxisome prolifera-
tor-activated receptor gamma (PPARγ) for its own replication in cytotrophoblasts. Here, we
investigated the molecular bases of PPARγ activation in infected cytotrophoblasts.
Results
We show that onboarded cPLA2 carried by HCMV particles is required for effective PPARγ
activation in infected HIPEC cytotrophoblasts, and for the resulting inhibition of cell migra-
tion. Natural PPARγ agonists are generated by PLA2 driven oxidization of linoleic and ara-
chidonic acids. Therefore, using HPLC coupled with mass spectrometry, we disclosed that
cellular and secreted levels of 13-hydroxyoctadecadienoic acid (13-HODE) and 15-hydro-
xyeicosatetraenoic acid (15-HETE) were significantly increased in and from HIPEC cytotro-
phoblasts at soon as 6 hours post infection. 13-HODE treatment of uninfected HIPEC
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recapitulated the effect of infection (PPARγ activation, migration impairment). We found
that infection of histocultures of normal, first-term, human placental explants resulted in sig-
nificantly increased levels of secreted 15-HETE and 13-HODE.
Conclusion
Our findings reveal that 15-HETE and 13-HODE could be new pathogenic effectors of
HCMV congenital infection They provide a new insight about the pathogenesis of congenital
infection by HCMV.
Introduction
Human cytomegalovirus (HCMV) is a beta herpes-virus which distribution ranges from 60 to
90% seropositive adults worldwide. HCMV infects and/or replicates in a broad spectrum of
organs and cell types. Lifelong latency is established after a primary infection. Infection by
HCMV is the most frequent congenital infection worldwide and a public health issue [1]. Pri-
mary infection of a seronegative mother during pregnancy, or less frequently, secondary infec-
tion in or reinfection of a seropositive mother, occurs in 0.2–2% of pregnancies and poses a
30% to 40% risk of vertical transmission to the fetus. Fetus infection may result in permanent
sensorineural and neurological disabilities that affect thousands of patients each year in the
USA (0.1–0.2% of all live births) [1, 2]. The most frequent permanent sequelae include mental
and/or psychomotor disability, sensorineural hearing or vision loss, and/or spastic cerebral pal-
sies, with or without orthopedic issues [3]. The direct annual costs of caring for congenitally
infected patients are estimated at $1-$2 billion in the USA [2]. Congenital disease is more
severe when primary maternal infection occurs in the first trimester. No vaccine is available
and no reliable prognosis tool is available so far, except ultrasound examination of macroscopic
brain abnormalities. Considering the dramatic health and societal cost of congenital HCMV
infection, as well as the critical role of placenta in the disease, a better insight on its pathogene-
sis is urgently needed to provide new therapeutic and prognostic tools.
Not only placenta is the portal of entry of HCMV virions to fetus [4], it is also a genuine tar-
get of infection. Infection causes placenta dysfunction, which is thought to result in intrauter-
ine growth restriction (IUGR), pre-eclampsia-like symptoms, miscarriages and probably
stillbirth [5]. Also, placenta is an endocrine organ, which, if infected, may release deleterious
soluble factors to the bloodstream or the fetus, such as inflammatory mediators or markers of
infection. After infection of the uterus from ascending or hematogenous route, HCMV ampli-
fies in the decidua, which refers to the endometrial stroma during pregnancy. Next, HCMV
spreads to and replicates within the adjacent placenta in fibroblasts, fetal capillaries and two
key placenta cell types, namely villous and extravillous cytotrophoblasts. The villous cytotro-
phoblasts (VCT) are epithelial progenitor cells, which underlie and differentiate to syncytiotro-
phoblasts (ST). STs populate the specialized syncytium layer surrounding the chorionic villi
that float in maternal blood, and form the maternal-fetal exchange barrier. The extravillous
cytotrophoblasts (EVCT) arise from the same progenitors than VCTs, invade the decidua,
forming cell columns dedicated to anchor the placenta to the uterine wall, and drive vascular
remodeling [6]. Infected placentas undergo villitis with lymphohistiocytic infiltrates. Placentas
infected in early gestation show long-standing damage and fibrosis at the uterine-placental
interface, which results in a hypoxic intrauterine environment [6]. In infected placentas from
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patients with IUGR, significant increase in the number of large fibrinoids with avascular villi,
edema, and inflammation were observed [7].
At the molecular level, we previously showed that HCMV activates peroxisome prolifera-
tor-activated receptor gamma (PPARγ) to favor its replication in cytotrophoblasts, leading to
inhibition of cytotrophoblast migration [8]. PPARγ is a ligand-activated nuclear receptor,
critical in placentation and trophoblast biology [9]. Natural PPARγ ligands include 15-deoxy-
Δ12,14 prostaglandin (PG) J2 (15d-PGJ2), 15-hydroxyeicosatetraenoic acid (15-HETE), 9- or
13-hydroxyoctadecadienoic acid (9/13-HODE) [9] (Table 1).
15d-PGJ2 arises from hydroxylation of the precursor PGD2. PGD2, 15-HETE, and 9/13-
HODE are generated by oxidization of arachidonic acid (AA) or linoleic acid (LA) by cyclooxy-
genase (COX) or 5-/15- lipoxygenase (LOX). Our previous findings raised the possibility that
activation of PPARγ in HCMV-infected trophoblast cultures could be mediated by soluble, yet
unidentified, ligands [8]. Characterization of PPARγ ligands mobilized during HCMV infec-
tion is therefore critical for a better understanding of the host cell response. Here, we investi-
gated which ligands account for PPARγ activation, both in the human cytotrophoblast line
HIPEC [10] and in placental explants at early steps of HCMV infection.
Materials and Methods
Ethics statement
The study was performed in accordance with the French ethical guidelines and was approved
by the local ethics committee of the Toulouse Children University Hospital. In this study, sam-
ples of first trimester placenta (8–11 week amenorrhea) from healthy women undergoing vagi-
nal elective termination of pregnancy were obtained. Written informed consent was obtained
from all study participants prior to sample collection. All placenta samples were anonymized
before processing. Placenta samples were used only for histoculture, as described in the present
article. All samples were destroyed after experimentation.
Cells, viruses and reagents
Human immortalized extravillous cytotrophoblasts (HIPEC) were propagated in DMEM/F12
(1/1; Life technologies) containing 10% fetal calf serum (Life technologies), penicillin (100 IU/
ml; Life technologies) and streptomycin (100 μg/ml; Life technologies), as described previously
[10]. The human immortalized fibroblast line MRC5/CCL171 (ATCC, Manassas, VA, USA)
was cultured in DMEM containing 10% bovine calf serum, penicillin and streptomycin.
We used laboratory-adapted AD169 (ATCC) or clinical VHL/E (a gift from C. Sinzger,
Tubingen, Germany) HCMV strains to infect HIPEC or placenta explants, respectively. Low
passage (<8 passages from the parent stock) VHL/E HCMV strains were used. For virus
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production, virus stocks were collected from infected MRC5 cells when cytopathic effects were
>90%. Supernatants were clarified by centrifugation at 1,500 × g for 10 min, ultracentrifuged
at 100,000 × g for 30 min at 4°C, resuspended in culture medium, and stored at −70°C until
use. Virus titers were determined upon infection of MRC5 cells by serial dilutions of the inocu-
lum followed by immunofluorescence analysis to count the number of nuclei immunoreactive
to HCMV Immediate Early antigen (IE) 24h post infection (pi)(fluorescence unit forming
assay). UV irradiation of HCMV particles was performed for 30 min in a closed propylene
tube with a Spectrolyne irradiator (EF-140/F fitted with a BLE-2537S bulb, Spectronics corpo-
ration, Westbury, NY). In these conditions, HCMV virions were able to infect cells, as checked
by immunostaining with an antibody specific to the tegument protein pp65 (Virusys corpora-
tion, Taneytown, MD), 30 minutes post infection; the viral genome could not be expressed, as
checked by the absence of immunoreactivity to the HCMV Immediate Early antigen (IE)
(Argene, Verniolle, France) 24h post infection (S1 Fig).
HIPEC were infected at a multiplicity of infection of 10 unless indicated. In these condi-
tions, approximately 80% of cells are infected 24h post infection, as assessed by the number of
cells immunoreactive to an antibody specific to HCMV Immediate Early (IE) antigen (Argene)
in immunofluorescence analysis. To inactivate onboarded PLA2, viral suspensions were treated
for one hour at room temperature by 50 μMmethyl arachidonyl fluorophosphonate (MAFP;
Enzo Lifesciences), ultracentifuged at 100,000 × g for 30 min at 4°C, washed twice with phos-
phate-buffered saline (PBS; Life technologies), and resuspended in culture medium. The work-
ing concentration of MAFP (50 μM) was determined by immunofluorescence analysis using
HIPEC infected by HCMV particles treated by various doses of MAFP, and an antibody spe-
cific to HCMV Immediate Early (IE) antigen (Argene). Cell viability was checked by 406-dia-
mino-2-phenylindole (DAPI) staining. Control viral suspensions were processed identically
after incubation in the presence of the vehicle (DMSO) instead of MAFP. When HIPEC were
infected with MAFP-treated virus, control uninfected HIPEC were cultured in the presence of
MAFP at a concentration equivalent to that which would have been obtained without the
HCMV particles washes (50 nM).
PPARγ synthetic activator was rosiglitazone (1 μM) (Sigma), and a stimulation time of 2h
was used. PPARγ specific inhibitor was GW9662 (2 μM; Calbiochem), and cells were incubated
with GW9662 one hour before infection. Optimal concentrations of rosiglitazone and
GW9662 were determined from initial dose-effect experiments using the luciferase PPAR
reporter plasmid (as detailed below). Cell viability was checked on the basis of Trypan blue
exclusion, normal cell morphology, and absence of nuclei condensation or fragmentation using
DAPI staining. The vehicle was assayed as a control in all experiments. Synthetic 15-HETE and
13-HODE were purchased (Sigma).
Onboarded cPLA2 assay
Control, UV- irradiated, or MAFP- treated AD169 suspensions (5.107 infectious particles/ml)
were incubated for 1h at 37°C in the presence of the fluorescent substrate bodipy-phosphatidyl-
choline in PBS (100 μM; Sigma). Reaction was terminated by adding one volume of PBS/buta-
nol-1 (v/v). Samples were then vortexed and centrifuged (5 min, 4°C at 16,000 g). The aqueous
fraction was discarded, and the remaining lipids in the butanol phase were collected, dried
under nitrogen, resuspended in 20 μl of chloroform-methanol-H2O (v/v/v), and loaded onto
thin layer chromatography (TLC) plates. TLC was performed using chloroform-methanol-ace-
tic acid-H2O (75/45/12/6; v/v/v/v). Fluorescence was revealed under UV light. Commercially
available phospholipase A2 (lecithinase from Naja naja venom; Sigma) was used as positive
control, and 0.5 U were incubated directly with bodipy-phosphatidylcholine.
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Luciferase reporter assays
We used a firefly luciferase (Luc) reporter plasmid based on a pGL4 backbone (Promega,
Madison, WI, USA) and containing three PPAR responsive elements (PPREs) [8] upstream
the herpes simplex thymidine kinase promoter (pGL4-PPRE-TK-luc). For normalization, we
used a promoter-less renilla luciferase plasmid (pRL-null, Promega). Actively growing HIPEC
were seeded in 96-well plates at a density of 25,000 cells per well. Transfection of both the
reporter and normalization plasmids was performed 16 h after seeding using Genejuice trans-
fection reagent (Novagen), according to the manufacturer's instructions. Cells were infected
with HCMV, HCMV treated by MAFP beforehand, and/or stimulated with rosiglitazone
(1 μM), in the presence or absence of MAFP (50 μM) or GW9662 (2 μM) in the culture
medium, during the 48 h following transfection. Cell lysis was performed using Cell Culture
Lysis Reagent (Promega). Luciferase activity was quantified using a Centro luminometer
(Berthold).
Oil Red O staining
HIPEC were treated by 10 μM 13-HODE or by the vehicle (DMSO), fixed in formaldehyde 4%
for 30 min, washed in PBS and isopropanol 30% and then incubated for 5 min with Oil Red O
solution (200mg/ml) diluted in isopropanol 30% (v/v). After washing with water, nuclei were
counterstained with Harris hematoxylin (1 min), washed and observed by microscopy.
Migration assays
For Wound healing assays, HIPEC monolayers (80% confluent) were infected or not by
AD169 (MOI 3; non treated, UV- irradiated or MAFP- treated) in the presence or absence of
GW9662 or rosiglitazone. In these conditions, using the live HCMV inoculum, approximately
50% of cells are infected 24h post infection, as assessed by the number of cells immunoreactive
to an antibody specific to HCMV Immediate Early (IE) antigen (Argene) in immunofluores-
cence analysis. Cultures were scratched manually (three scratches per well) 6 h post infection,
and left for 24 h at 37°C. The next day, pictures of the scratches were shot in bright field using
an automated microscope (Apotome 2, Zeiss). Three fields were shot per condition. The coor-
dinates of each field were saved by using a macro-command in the software driving the micro-
scope (Zen, Zeiss), so that exactly the same field was shot at day 2. Next, pictures were analyzed
by using ImageJ software (11). The difference between the area of the scratch in each field at
days 1 and 2 was measured, and represented the surface of migration of the corresponding cell
monolayer (S). Last, the index of migration (IM) was determined by normalizing S of all assays
respective to the value of S for the control assay. Results are expressed as the percent variation
of IM relative to the control.
Transwell migration assays were performed as described elsewhere [10] with slight modifi-
cations. HIPEC were cultured for 48 h in the presence or absence of 1 μM rosiglitazone, 2 μM
GW9662, 50 nMMAFP, or infected by live, UV-irradiated, or MAFP-treated, VHL/E HCMV
at a MOI of 3. The medium was renewed after 24h. After 48h, the transwell inserts were washed
three times with PBS and cells were fixed for 20 min in methanol at -20°C, washed three times
with PBS, and stained with DAPI. Filters were examined and photographed on a Leica
DM4000B microscope. The number of nuclei detected on the filter was determined using the
ImageJ software, the Fast Morphology plug-in, and a threshold size of 400 pixels square. When
required, cell clusters were resolved manually using the Cell Counter plug-in. The data were
normalized to the number of nuclei obtained in the control (non infected, non treated) experi-
ment. Two independent experiments were performed. Statistical analysis was performed using
the Mann-Whitney and Kruskal-Wallis tests.
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High performance liquid chromatography coupled to tandemmass
spectrometry (LC-MS/MS)
LC-MS/MS was performed as detailed elsewhere [11], using HPLC grade methanol, methyl
formate, and acetonitrile (Sigma–Aldrich). Deuterium-labeled lipoxin A4 (LxA4-d5), leukotri-
ene B4 (LTB4-d4) and 5- hydroxyeicosatetraenoic acid (5-HETE-d8) (Cayman Chemicals)
were mixed at a concentration of 400 ng/ml in MeOH and used as the internal standard (IS)
solution. VHL/E strain was used to infect HIPEC monolayers. In all experiments, HIPEC from
10 cm² culture wells were harvested 6 h post infection in 0.2 ml of PBS, transferred to lysing
matrix A (MP Biomedicals) and supplemented with 5 μl of IS solution.
Cells were lysed using a spin homogeneizer (Fastprep, MP Biomedicals) with 2 cycles of
20 sec at 5 000 rpm. 10 μl of the lysed cell suspension were added to 200 μl of 0.1 M NaOH for
subsequent protein quantification using a Bradford assay (BioRad). The remaining of the lysate
was supplemented with 200 μl methanol, vigorously shaken, and centrifuged for 15 min at
1 000 x g at 4°C. The supernatants were collected and stored at -80°C until lipid extraction. Lipid
amounts from cell lysates were expressed in pg per mg of protein in the lysate. HIPEC culture
supernatants were collected 6 hours post infection, supplemented with 300 μl of ice cold metha-
nol and 5 μL of IS solution, clarified by a centrifugation at 1000g for 15 minutes, and stored at
-80°C until lipid extraction. Lipid amounts from supernatants were expressed as pg/ml.
Lipid preparation from all samples was carried out through solid-phase extraction using
hydrophobic polystyrene-divinylbenzene resin in dedicated 96-well plates (Chromabond
multi96 HR-X 50 mg; Macherey-Nagel). After conditioning of the plate with methanol and
sample loading, the plates were washed twice with H2O/MeOH (90/10, v/v) and dried under
aspiration for 15 min. Lipids were eluted with methanol (2 ml), dried under nitrogen, dissolved
again in methanol (10 μl) and transferred to liquid chromatography tubes before LC–MS/MS
analysis.
LC-MS/MS analysis was performed using an UHPLC system (LC1290 Infinity, Agilent)
coupled to a 6460 triple quadrupole mass spectrophotometer (Agilent Technologies) fitted with
electro-spray ionization interface. Separation was done at 40°C on a Zorbax SB-C18 column
(2.1 mm–50 mm–1.8 μm) (Agilent Technologies). The compositions of mobile phase A and B
were water, acetonitrile (ACN) and formic acid (FA) (75/25/0.1) and ACN, FA (100/0.1), respec-
tively. Compounds were separated with a linear gradient from 0 to 85% B in 8.5 min and then to
100% B at 9 min. Isocratic elution continued for 1 min at 100% B, then 100% A was reached at
10.2 min and maintained to 11 min. The flow rate was 0.35 ml/min. The autosampler was set at
5°C and the injection volume was 5 μL. Source conditions were as follows: negative ESI mode;
source temperature = 325°C, nebulizer gas (nitrogen) flow rate = 10 L/min, sheath gas (nitrogen)
flow rate = 12 L/min, sheath gas temperature = 400°C and spray voltage = −3500 V. Data were
acquired in MRMmode. For each compound the best conditions of separation and quantifica-
tion were defined: retention time in minute (RT), specific Q1/Q3 transition (T) fragmentor (F)
and collision energy (CE). Peak detection, integration and quantitative analysis were performed
using Mass Hunter Quantitative analysis software (Agilent Technologies). At least three indepen-
dent experiments were performed, each in triplicate wells.
Placenta histoculture assays
Twelve first trimester HCMV-negative placentas (8–11 weeks amenorrhea) were obtained fol-
lowing elective abortions carried out by vacuum aspiration at the Paule de Viguier Hospital
(Toulouse, France). Fresh placentas were processed as described elsewhere [12]. We used
method B according to Lopez et al [12]. Briefly, 3 x 105 MRC5 cells were seeded in 10 cm² wells
5 days before placenta collection, and were infected by HCMV (VHL/E strain) at a MOI of 3
PPARγ Agonists in HCMV Infected Placenta Cells and Explants
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the day after. Collected placenta was washed with DMEM supplemented with 15% FCS, 1%
penicillin-streptomycin, 0.1% gentamicin, 1% amphotericin B, and cut to obtain several villi
blocks of approximately 3 mm². Blocks were placed onto sterile gelatin sponge substrates (Gel-
foam) at the air-liquid interface, in 10 cm² culture wells containing infected MRC5 cells or
uninfected MRC5 for the control (day 0). There was no direct contact between the MRC5 cells
and the placental blocks. At day 5 post infection, the placental explants were placed into new
10 cm² wells without supporting MRC5 layer, washed three times with PBS, and left in fresh
culture medium. The culture media were collected at days 6 and 12 post infection and stored at
-80°C until lipid analysis
Statistical analysis
Statistical analyses were performed with the StatEL plugin (Adscience) for Excel (Microsoft)
using Kruskal-Wallis test, except for data from placenta histoculture assays, which were ana-
lyzed with the Prism program (Graphpad) using the Wilcoxon test. Error bars are SEM. p val-
ues<0.05 or less were considered significant.
Results
HCMV particles carry onboarded cPLA2 activity
We first investigated the biochemical bases of the generation of PPARγ agonists derived from
polyunsaturated fatty acids (PUFA) in infected HIPEC. Release of arachidonic acid (AA) and
linoleic acid (LA) from membrane glycerophospholipids is catalytically driven by calcium-
dependent phospholipase A2 (cPLA2) [13]. It has been demonstrated that HCMV particles
carry an onboarded, host cell-derived cPLA2 activity (oPLA2), required for virus replication
[14]. We hypothesized that oPLA2 delivered to the infected cell could contribute to the biosyn-
thesis of PPARγ activators. Since UV-irradiated HCMV does not activate PPARγ in HIPEC
[8], we first investigated whether UV irradiation abolished o PLA2 activity in HCMV particles
(Fig 1A). To determine whether HCMV virions carried active oPLA2, we examined the hy-
drolysis of a fluorescent bodipy-phosphatidylcholine substrate (B-PC) to bodipy-lysophospha-
tidylcholine (B-LPC) when incubated in the presence of HCMV particles. In this assay,
generation of B-LPC thus indicates PLA2 activity. Thin layer chromatography showed B-LPC
generation from B-PC incubated with native HCMV particles (Fig 1A). PLA2 activity was
detected from B-PC incubated with UV-irradiated HCMV particles, indicating that UV irradi-
ation did not inactivate this oPLA2 (Fig 1A). In contrast, HCMV particles treated beforehand
by the specific PLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP) showed efficient
inhibition of oPLA2 (Fig 1A). These data show that HCMV particles actually carry onboarded
cPLA2, which is sensitive to inhibition by MAFP, but not to UV irradiation. Therefore, we used
MAFP to inactivate o PLA2 in subsequent experiments.
Onboarded cPLA2 activity is required for effective PPARγ activation and
for inhibition of HIPECmigration
We had previously shown that only transcriptionally competent HCMV particles were able to
cause PPARγ activation in HIPEC [8]. It was however unknown whether lipid mediators gen-
erated from LA or AA through o PLA2 activity actually contribute to PPARγ activation. Hence,
we investigated whether MAFP-treated HCMV particles were able to activate PPARγ in
HIPEC by using a PPARγ -reporter luciferase assay (Fig 1B). As expected, infection by native
HCMV particles induced a dramatic and significant (p<0.01) increase in PPARγ activity in
HIPEC (Fig 1B). Likewise, stimulation of uninfected HIPEC by the selective PPARγ ligand
PPARγ Agonists in HCMV Infected Placenta Cells and Explants
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rosiglitazone [15] also resulted in significant activation (Fig 1B). PPARγ activation was strongly
and significantly inhibited when HIPEC were cultured in the presence of the PPARγ selective
ligand GW9662 [16], even if stimulated by rosiglitazone or infected by live HCMV (Fig 1B).
We also investigated the effect of MAFP treatment of HCMV particles upon PPARγ activation
in HIPEC. In our system, it is very unlikely that HIPEC had been in contact with active doses
of MAFP, since viral particles were carefully washed by ultracentrifugation before being used
to infect HIPEC. In any event, to rule out any effect from possible contaminant MAFP in the
inoculum, we performed control assays with uninfected HIPEC in the presence of MAFP at a
concentration equivalent to that would have been obtained without the HCMV particles wash,
i.e., 50 nM. We found no detectable effect of MAFP on PPARγ activity in these control assays
(Fig 1B). In contrast, we observed that infection of cytotrophoblasts with MAFP-treated
HCMV particles abolished PPARγ activation associated with infection (Fig 1B). These findings
suggested that oPLA2 activity from HCLMV particles is required for effective PPARγ activation
in HIPEC.
We further explored the impact of oPLA2 on infected HIPEC. We previously reported that
PPARγ activation in HIPEC impairs cell migration, should PPARγ be activated by rosiglita-
zone stimulation or HCMV infection [8]. Therefore, we investigated whether MAFP-treated
Fig 1. Onboarded cPLA2 is required for PPARγ activation and inhibition of cytotrophoblast migration. (A) TLC analysis of bodipy-phosphatidylcholine
(B-PC) incubated in the presence of buffer (mock), purified PLA2 (PLA2), native HCMV particles (HCMV), HCMV particles pre-treated by MAFP (HCMV+
MAFP) or UV-irradiated (HCMV-UV). (B) PPARγ activity luciferase assay performed with HIPEC in various conditions, using a reporter plasmid responsive to
PPARγ (pGL4-PPRE) or a control plasmid (PGL4), 48 h pi or post treatment onset. HCMV: HIPEC infected by live HCMV particles; vi: the viral inoculum was
treated beforehand by MAFP; cm: control with 50 nMMAFP in the culture medium; GW: PPARγ inhibitor GW9662; Rosi: PPARγ agonist rosiglitazone. RLU:
relative luciferase units; **: p < 0.01 (Kruskal-Wallis test). The assay was repeated twice.(C) Wound-healing assays. HCMV+MAFP: the viral inoculum was
treated beforehand by MAFP; HCMV+GW: the HIPEC were infected in the presence of GW9662; HCMV-UV: the viral inoculum was UV-irradiated. Results
are expressed as the percent variation relative to the control. The figure shows results of a representative experiment, out of two independent experiments,
each comprising triplicate measures. NI: non-infected.
doi:10.1371/journal.pone.0132627.g001
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HCMV particles altered HIPEC migration abilities by using wound-healing assays (Fig 1C).
Infection of cytotrophoblasts with MAFP-treated HCMV particles decreased PPARγ-depen-
dent inhibition of cell migration in a manner similar to that caused by UV irradiation of the
inoculum, or by treatment of HIPEC with the PPARγ synthetic inhibitor, GW9662 (Fig 1C).
Altogether, these results suggest that oPLA2 is required for PPARγ activation and inhibition of
cytotrophoblast migration.
15-HETE and 13-HODE are the predominant PUFA-derived agonists of
PPARγ in infected HIPEC
We next hypothesized that o PLA2 activity contributes to the biosynthesis of PPARγ ligands in
infected HIPEC. This prompted us to search for PPARγ activating lipids generated in HIPEC
at early stages of infection. To identify putative PPARγ activators generated among AA or LA
metabolites, we used a novel, rapid and sensitive method based on high performance liquid
chromatography coupled to tandem mass spectrometry (LC-MS/MS) [11] using lysates and
conditioned culture media collected at 6 hours pi (Fig 2A). Candidate PPARγ agonists were 9/
13-HODE, 15-HETE, and 15d-PGJ2. We also investigated the amounts of other PUFA-derived
lipids: 8/12-HETE, which have not been identified as PPARγ agonists to date, and PGD2,
because it is the precursor of 15d-PGJ2. The optimal conditions determined for lipid separation
for each compound are provided (Table 2).
For each metabolite, we also determined retention time, line equation, coefficient of deter-
mination, maximum percent residual, limit of detection and quantification (Table 3).
LC-MS/MS analysis revealed a wide range of PUFA-derived lipids in HIPEC or in condi-
tioned culture media (Fig 2A). No PGD2, 15d-PGJ2, or 8/12-HETE could be detected from the
culture supernatants of infected or control HIPEC (Fig 2A). There was no change in the
amounts of 15d-PGJ2 or 8 /12-HETE in infected HIPEC as compared to the uninfected con-
trols (Fig 2A). Likewise, no significant change was observed in levels of cellular or secreted
9-HODE in infected HIPEC as compared to the controls (Fig 2A). In contrast, we found mod-
erately but significantly increased levels (approximately 1.5 fold) of 15-HETE in lysates (p<
0.02) or supernatants (p< 0.029) from HCMV-infected HIPEC as compared to the uninfected
controls (Fig 2A). 15-HETE amounts in uninfected control cell lysates were detected at 459 pg
(1.4 pmol) per mg of protein and rose to 659 pg (2 pmol) per mg of protein in infected HIPEC.
In the conditioned culture supernatants, these amounts were measured at 164 pg/ml (0.5 nM)
in uninfected cultures, compared to 316 pg/ml (0.9 nM) in infected cultures. In addition,
LC-MS/MS analysis revealed a strong (> 2.4 fold) and significant (p< 0.021) increase in the
mean amount of 13-HODE secreted from HCMV-infected HIPEC (Fig 2A). Indeed, amounts
of 13-HODE were far greater than that of 15-HETE. Secreted 13-HODE amounts in superna-
tants ranged from 282 pg/ml (0.9 nM) in uninfected HIPEC cultures to 3,056 pg/ml (9.8 nM)
in infected HIPEC cultures. We also observed a significant, albeit moderate (>1.4 fold, p<
0.026), increase in the mean amount of 13-HODE in infected HIPEC lysates (Fig 2A). Cyto-
plasmic 13-HODE amounts ranged from 1,091 pg/mg of protein (3.7 nM) in uninfected
HIPEC to 1,674 pg/mg of protein (5.6 nM) from infected HIPEC (Fig 2A). Amounts of
13-HODE and 15-HETE were not significantly different from uninfected controls when the
inoculum was irradiated by UV light (Fig 2A). In contrast, infection by HCMV particles treated
beforehand by MAFP abolished the increase in the quantity of secreted 13-HODE and
15-HETE 6 h pi (Fig 2B), indicating that active oPLA2 is needed for their efficient biosynthesis.
13-HODE and 15-HETE have been well characterized as bona fide PPARγ agonists [9, 17].
We nevertheless verified the ability of such PUFA-derived agonists to activate PPARγ in
HIPEC, using 13-HODE as a model. Treatment of uninfected HIPEC by 10 nM 13-HODE
PPARγ Agonists in HCMV Infected Placenta Cells and Explants
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Fig 2. 15-HETE and 13-HODE are released by HIPEC infected by live HCMV. (A) LC-MS/MS analysis of the PUFA-derived lipids in HIPEC uninfected
(NI), infected with live HCMV (HCMV) or UV-irradiated HCMV (UV-HCMV) (expressed as pg/mg of protein) and from the corresponding culture supernatants
(expressed as pg/ml). (B) LC-MS/MS analysis of 13-HODE and 15-HETE in the culture medium of HIPEC uninfected (NI), infected by live HCMV (HCMV) or
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induced accumulation of lipid droplets, indicative of active PPARγ (Fig 2C). We also checked
whether 13-HODE and/or 15-HETE treatment altered the migratory properties of HIPEC.
Preliminary wound healing assays showed that treatment of uninfected HIPEC by 13-HODE
reduced cell migration in a dose-dependent manner, recapitulating the effect of infection, simi-
larly to rosiglitazone stimulation (Fig 2D). Because HIPEC retain the invasive properties of pri-
mary EVCT [10], we next investigated the outcomes of 13-HODE or 15-HETE treatment on
HIPEC migration capacities using transwell migration assays. As expected, a significant
decrease in migration was found in infected HIPEC (p<0.0015) or uninfected HIPEC stimu-
lated by rosiglitazone (p<0.0065) as compared to the uninfected, untreated controls (Fig 2E).
This inhibition of migration was strongly attenuated when HIPEC were infected by live
HCMV in the presence of the PPARγ inhibitor GW9662 (Fig 2E). Treatment of HIPEC by
GW9662 or MAFP, or culture of HIPEC in the presence of UV irradiated HCMV did not result
in any significant change in migration as compared to the control (Fig 2E). GW9662 treatment
caused a slight, albeit non significant (p<0.73), increase in migration, probably through inhibi-
tion of basal PPARγ activity in HIPEC. Noteworthy, incubation of HIPEC in the presence of
MAFP-treated HCMV showed a significant decrease in migration as compared to the unin-
fected control (p<0.034) (Fig 2E), possibly because of endogeneous PLA2 activity substituting
for that of oPLA2 within the 48 hours of incubation. Lastly, stimulation by 13-HODE or
15-HETE resulted in significant, dose-dependent, impairment of migration as compared to the
unstimulated controls (p<0.004), what confirmed that 13-HODE and 15-HETE showed anti-
migratory properties upon HIPEC.
Placenta histocultures secrete increased amounts of 15-HETE and
13-HODE when infected by HCMV
Next, we investigated which PPARγ activator lipids are released upon infection by HCMV
using a model closer to the physiological context. To this aim, we used an histoculture model
by HCMV treated by MAFP (HCMV-MAFP). (C) Red Oil O staining of uninfected HIPECs stimulated by 13-HODE or treated by the vehicle (DMSO). (D)
Wound healing assay using uninfected HIPEC treated by different doses of 13-HODE, rosiglitazone (Rosi), or the vehicle (DMSO), or untreated (NT). The
results shown are from one representative experiment, out of two independent experiments, each comprising triplicate measures. (E) Transwel migration
assay using uninfected HIPEC or HIPEC infected by live HCMV (HCMV), UV-irradiated HCMV (HCMV-UV) or HCMV treated by MAFP (HCMV-MAFP)
(MOI = 3), in the presence or the absence of 1μM rosiglitazone, 2 μMGW9662 (GW), 50 nMMAFP (MAFP), or 13-HODE (13-HODE) or 15-HETE (15-HETE)
at various concentrations (nM). Shown are the results of two independent experiments. *: p < 0.05; **: p < 0.01; ***: p < 0.001.
doi:10.1371/journal.pone.0132627.g002
Table 2. Optimal conditions for lipid separation by LC-MS/MS.
Compounds Q1/Q3 transition Fragmentor (V) Collision energy (V)
LxA4-d5* 356/115 100 6
PGD2 351/271 100 12
15d-PGJ2 315/271 90 2
LTB4-d4* 339/197 120 6
13-HODE 295/195 140 8
9-HODE 295/171 135 8
15-HETE 319/219 110 2
12-HETE 319/208 110 2
8-HETE 319/155 110 4
5-HETE-d8* 327/155 100 2
* Deuterated compound used as an internal standard.
doi:10.1371/journal.pone.0132627.t002
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of normal human placental explants that can be infected ex vivo by HCMV and that we
described elsewhere [12]. First trimester placenta blocks were obtained from 12 donors and
cultured 5 days at the air-liquid interface in the presence of VHL/E-HCMV-producing MRC5
fibroblasts to allow efficient infection. At day 6, placental explants were transferred to
MRC5-free culture wells for 1 day or 6 days before culture supernatants were collected for lipid
analysis. We used explants from first trimester placenta, since they contain a greater number of
invasive extravillous cytotrophoblasts than later stages and because congenital HCMV infec-
tion during first trimester confers the most damage to the placenta and/or the fetus. We thus
assumed that early placental explants were more likely to recapitulate the situation in vivo.
Indeed, we found that only placenta explants growing on supporting infected MRC5 layer
could be efficiently infected by HCMV. MRC5 showed no productive infection when the viral
inoculum was either UV irradiated or MAFP treated beforehand. 8/12/15-HETE 9/13-HODE,
PGD2 and 15d-PGJ2 were detectable by LC-MS/MS from 24 hours post installation of the
explants in the MRC5-free wells (Fig 3). Although baseline levels were variable among donors,
we observed significantly greater amounts of secreted 15-HETE (p< 0.029) and 13-HODE (p<
0.008) in the infectious context when compared to those from the same donor installed on
uninfected MRC5, with levels increasing from 1,250 pg/ml (4.2 nM) to 14,600 pg/ml (49 nM)
(for 13-HODE) or from 1,007 pg/ml (3 nM) to 14,239 pg/ml (44.5 nM)(for 15-HETE) at day 6
post installation (Fig 3). Statistical analysis confirmed that secreted levels of 13-HODE and
15-HETE were significantly greater in the infected explants as compared to the controls (p<
0.01 and p<0.05, respectively). At day 12, we observed no significant difference in the amounts
of 15-HETE or 13-HODE from the histocultures placed in the infectious context as compared
as the controls, although their mean values were greater than those at day 1 pi (Fig 3). This sug-
gested that increased amounts at day 12 did not result from increasing number of infected cells
within the placenta explants. More importantly, this indicated that secretion of 15-HETE and
13-HODE were rather associated with early stages of infection. In contrast, amounts of PGD2,
15d-PGJ2, 8/12-HETE and 9-HODE were not increased in infected histocultures, at day 6 or
12 (Fig 3A). HCMV infection of the placental explants was checked by immunohistological
staining using the antibody specific to IE. Infected explants, but not control explants, showed
clear IE immunoreactivity in endothelial, stromal and, mostly, in cytotrophoblasts cells (Fig
3B). Our findings suggest that infection of early placenta results in enhanced secretion of
13-HODE and 15-HETE.
Discussion
Congenital infection by HCMV is the most frequent congenital infection and accounts for dev-
astating sensorineural and neurodevelopmental sequelae in the severe cases. It also causes
Table 3. Retention time (RT), line equation, coefficient of determination (r2), maximum percent residual, limit of detection (LOD), limit of quantifica-
tion (LOQ) and attributed internal standard (IS) for eachmetabolite.
Compound name RT min Equation r² Max % Residual LOD ng/mL LOQ ng/mL IS
PGD2 3.87 y = 1.767076 * x + 1.199E-005 0.9996 1.872 0.24 0.49 LxA4-d5
15d-PGJ2 7.60 y = 4.119598 * x—5.150E-004 0.9978 10.177 0.24 0.49 LTB4-d4
9-HODE 7.99 y = 0.451368 * x + 8.281E-004 0.9997 3.420 0.12 0.24 5HETE-d8
13-HODE 7.96 y = 0.550079 * x + 0.0017 0.9966 3.980 0.48 0.98 5HETE-d8
15-HETE 8.19 y = 0.438428 * x—2.109E-005 0.9970 5.427 0.48 0.98 5HETE-d8
8-HETE 8.48 y = 0.322877 * x + 2.779E-005 0.9992 2.816 0.48 0.98 5HETE-d8
12-HETE 8.50 y = 0.095890 * x + 9.751E-005 0.9974 3.450 1.90 3.60 5HETE-d8
doi:10.1371/journal.pone.0132627.t003
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Fig 3. Increased amounts of 15-HETE and 13-HODE secreted by from early placenta explants infected by HCMV. (A) LC-MS/MS analysis of the
amounts of PUFA-derived lipids secreted from histocultures from 12 first trimester placentas either infected by HCMV (CMV) or uninfected (NI). *: p < 0.05;
**: p < 0.01 (Wilcoxon test). (B) Immunostaining analysis of HCMV antigen IE in infected (HCMV) or uninfected (NI) placental explants cultured ex vivo.
Representative views are shown. Note the positive, nuclear IE staining in the cytotrophoblast layer (ST) surrounding the villus stroma (S).
doi:10.1371/journal.pone.0132627.g003
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placenta dysfunction, which can be associated with pre-eclampsia (PE) like symptoms, IUGR
or even stillbirths, and may threaten other organs through the deleterious action of secreted
soluble mediators. Given the dramatic health and societal cost of congenital HCMV infection,
a better insight on its pathogenesis is needed to provide new therapeutic or prognostic tools.
Based on our previous demonstration that PPARγ activation is an early and key effector of
HCMV infection in cytotrophoblast cells [8], the goal of this study was to gain novel insight
about the modalities of PPARγ activation upon infection. Here, using newly-developed lipido-
mic approaches, we demonstrate that 15-HETE and 13-HODE are released by HIPEC and pla-
cental explants during the early steps of HCMV infection (Fig 4).
In this study, we used two HCMV strains, the laboratory-adapted AD169 and the clinical
strain VHL/E. The former harbors a 20-kb genomic deletion which makes the later a more
Fig 4. Proposedmodel of PPARγ activation in HCMV infection of placental cells.HCMV particles
(HCMV) carry onboarded cPLA2 (oPLA2) which catalyses linoleic acid (LA) and arachidonic acid (AA)
release from host membrane phospholipids (PL). AA and LA undergo oxidization driven by 15-lipoxygenase
(15-LOX), which generates 15HETE and 9-HODE, respectively. 15HETE and 9-HODE are activating ligands
of PPARγ, which dimerizes with RXR to regulate the expression of the host and virus genomes, resulting in
impaired migration abilities in vitro, and enhanced IE transcription and viral replication. M: cell membrane, C:
cytoplasm, N: nucleus.
doi:10.1371/journal.pone.0132627.g004
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relevant model given that it is used at low passages of amplification. Notably, we found similar
results respective to PPARγ activation, HIPEC migration, and onboarded PLA2 with AD169
HCMV than what had been reported before with VHL/E HCMV [8, 14]. However, to carry out
the LC-MS/MS screening, the experimental procedure and the relatively lower efficiency of
producing VHL/E stocks as compared to AD169 prevented us to use low passage VHL/E sus-
pensions. Therefore we elected to use AD169 rather than generate high passage VHL/E for the
initial screening in HIPEC, and we used low passage VHL/E for the screening in placental
explants. Noteworthy, 13-HODE and 15-HETE were the predominant lipids generated by
HIPEC infected by AD169 and by placental explants infected with VHL/E respectively. Also,
the results of transwell migration assays, performed with HIPEC infected by VHL/E HCMV,
supported those found in wound healing experiments with AD169. Together, these data sug-
gest that AD169 genome alterations do not result in detectable changes respective of HIPEC
permissivity and migration abilities, PPARγ activation and 13-HODE and 15-HETE
generation.
HIPEC are SV-40 immortalized human EVCT [10]. As such, they probably bear transcrip-
tome or genomic alterations. We failed to generate primary or secondary cultures of EVCT,
even from early placentas. Therefore, we elected to investigate the outcomes of infection in pla-
centa explants, a model more relevant to pathophysiology. Noteworthy, the results of the lipid
screen using HIPEC and placental explants were similar, showing increased biosynthesis of
13-HODE and 15-HETE in infected explants. However, the limitation of this study is the
impossibility to figure out which cell type(s) within the placenta explants actually generate(s)
13-HODE or 15-HETE, or to rule out the possibility of bystander stimulation of 13-HODE /
15-HETE biosynthesis between neighbor cell types within the placental explants.
The amounts of secreted 15-HETE were found at least 2 fold lower than those of cellular
15-HETE. We assumed that this could result from either low levels of secretion or poor stability
in the medium. The amounts of both cellular and secreted 13-HODE appeared much greater
than those of 15-HETE (> 3 fold), indicating more efficient biosynthesis and/or secretion.
We showed that PLA2 activity supplied by the virus (oPLA2) is mandatory for 15-HETE
and 13-HODE production, consistent with the fact that PLA2 drives AA and LA release from
membrane phospholipids. We have previously reported that UV-irradiated HCMV could not
activate PPARγ in HIPEC [8]. However, we showed here that UV irradiation had no impact on
either o PLA2 activity, using TLC analysis of HCMV particle lysates (Fig 1A), or on 13-HODE
or 15-HETE biosynthesis, by LC-MS/MS analysis using HIPEC infected by UV-irradiated
HCMV (Fig 2A). These findings suggest that o PLA2 is indeed required, but is not sufficient to
trigger PPARγ activation in HIPEC. Viral gene expression seems to be required, possibly
through the production of immediate early transcripts that remain to be investigated. These
may, in turn, modulate downstream stages of the cascade leading to 15-HETE or 13-HODE
biosynthesis.
The present study underscores the role of 15-LOX in HCMV-infected placenta, since
15-LOX is a shared catalytic driver of oxidization of AA or LA that leads to 15-HETE and
13-HODE synthesis. The 15-LOX pathway has been extensively investigated as a key regulator
of healthy and pathological vascular system, including vascular plasticity and remodeling; it
has been described as critical in the generation as well as the resolution of inflammation; and it
has been reported to exert pro-atherosclerotic and anti-atherosclerotic effects [18].
15-HETE was originally identified as a PPARγ agonist in monocytes and macrophages [19,
20], and, as such, could contribute to the anti inflammatory role of the receptor [21]. 15-HETE
is associated with PE or vascular pathogeny in a number of studies, and it has been reported to
exert important roles in umbilical cord vasoconstriction and vascular remodeling associated
with PE [22]. Increased release of 15-HETE in the placenta and in the venous and umbilical
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cord sera of patients with PE have been reported [23, 24], consistently with increased 15-LOX
activity in placenta from PE patients [22]. 15-HETE has been shown to promote HUVEC
endothelial cell line proliferation and migration [24]. Here, we found increased release of
15-HETE in histocultures from healthy placenta infected by HCMV ex vivo, outside any con-
text of PE. This finding suggests that 15-HETE secreted in placenta in response to HCMVmay
have a causative role in PE symptoms associated with congenital HCMV infection. 15-HETE
also enhances the expression of placenta growth factor (PLGF) [25]. PLGF is abundantly
expressed by trophoblasts and has been proposed to modulate vascular development, stability,
and/or function, within the decidua and placental villi [26]. The receptor for PLGF on tropho-
blast, called fms-like tyrosine kinase (flt-1) receptor, exists as a soluble form, s-flt-1. Strikingly,
s-flt-1 levels are increased in the amniotic fluid of patients with congenital HCMV infection
[27], and could thereby represent a negative modulation of excessive PLGF signal due to
increased levels of 15-HETE resulting from HCMV infection. Besides, 15-HETE appeared to
be also a negative regulator of 15-LOX isoform 2 gene expression through an autocrine feed-
back loop involving binding onto the 15-LOX-2 gene promoter of PPARγ activated by
15-HETE [28]. Lastly, 15-HETE is an endogenous regulator of prostacyclin, a prostanoid
which is a key regulator of vascular homeostasis during pregnancy in particular [29].
13-HODE was originally identified as a strong PPARγ ligand in the monkey kidney cell line
CV1 and in human macrophages [20]. Hence, similar to 15-HETE, 13-HODE contributes to the
anti-inflammatory role of the receptor [21]. In human trophoblasts, 13-HODE was previously
reported to increase human chorionic gonadotropin production but showed no effect on the dif-
ferentiation markers syncitin, cyclin E or p27 [17]. In addition to linoleic acid, oxidized low-den-
sity lipoproteins (oxLDL) are a natural source of 13-HODE [30–32]. 13-HODEmight play a role
in the inhibition of trophoblast invasion mediated by oxidized LDLs [33]. 13-HODE can also
modulate the immunological function of oxLDL: notably, the capacity of oxLDL to generate acti-
vating dendritic cells from differentiating monocytes was shown to be inhibited by the presence
of 13-HODE [34]. 13-HODE is also an activating ligand of the transient receptor potential vanil-
loid type 1 (TRPV1), a non-selective cation channel with a wide distribution throughout the cen-
tral and peripheral nervous systems [35, 36]. TRPV1 integrates painful stimuli, though the role of
13-HODE as such a mediator of inflammatory pain responses remains unclear [37]. It has been
proposed that PPARγmay be involved in the pathophysiology of IUGR and/or PE [38]. In PE,
lipid deposition in maternal spiral arteries, namely acute atherosis, resembles early stages of ath-
erosclerosis [39]. Yet, 13-HODE shows atherogenic activity and LDLs are abundant in athero-
sclerotic lesions [30]. Therefore, it is tempting to speculate that 13-HODE production might
have a role in the onset of PE-like symptoms.
In conclusion, we reveal that HCMV-infected HIPEC cytotrophoblasts and placental
explants release predominantly increased amounts of 15-HETE and 13-HODE, two PUFA-
derived mediators that lie at the crossroads of a number of pathways modulating inflammation
as well as vasculature, during pregnancy.
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S1 Fig. UV irradiation of HCMV particles does not prevent infection but abolishes expres-
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HCMV Immediate Early antigen (IE), performed 24 hours pi, in HIPEC infected by live
HCMV (live) or HCMV irradiated by UV light (UV), at a MOI of 3, or uninfected HIPEC
(NI). Scale bar: 25 μm.
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